After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations ...

With nutritional, pharmaceutical, and surgical options available for obesity, clinicians are being called upon to make ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...